The Arctic Investigations Program (AIP) began surveillance for invasive group A streptococcal (GAS) infections in Alaska in 2000 as part of the invasive bacterial diseases population-based laboratory surveillance program. Between 2001 and 2013, there were 516 cases of GAS reported, for an overall annual incidence of 5.8 cases per 100,000 persons with 56 deaths (case-fatality ratio, 10.7%). Of the 516 confirmed cases of invasive GAS, 422 (82%) had isolates available for laboratory analysis. All isolates were susceptible to penicillin, cefotaxime and levofloxacin. Resistance to tetracycline, erythromycin and clindamycin was seen in 11% (n=8), 5.8% (n=20) and 1.2% (n=4) of the isolates, respectively. A total of 51 emm types were identified, of which emm1 (11.1%) was the most prevalent followed by emm82 (8.8%), emm49 (7.8%), emm12 and emm3 (6.6% each), emm89 (6.2%), emm108 (5.5%), emm28 (4.7%), emm92 (4%) and emm41 (3.8%). The five most common emm types accounted for 41% of isolates. The emm types in the proposed 26-valent and 30-valent vaccines accounted for 56% and 78% of all cases, respectively. GAS remains an important cause of invasive bacterial disease in Alaska. Continued surveillance of GAS infections will help improve understanding of the epidemiology of invasive disease, with impact on disease control, notification of outbreaks, and vaccine development.